Vor Biopharma Future Growth

Future criteria checks 2/6

Vor Biopharma is forecast to grow earnings and revenue by 11% and 74.1% per annum respectively while EPS is expected to grow by 22.4% per annum.

Key information

11.0%

Earnings growth rate

22.4%

EPS growth rate

Biotechs earnings growth	29.6%
Revenue growth rate	74.1%
Future return on equity	n/a
Analyst coverage	Good
Last updated	06 Sep 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

NasdaqGS:VOR - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	8	-119	-82	-125	6
12/31/2025	1	-114	-113	-105	7
12/31/2024	N/A	-113	-116	-101	7
6/30/2024	N/A	-118	-105	-104	N/A
3/31/2024	N/A	-120	-108	-106	N/A
12/31/2023	N/A	-118	-101	-100	N/A
9/30/2023	N/A	-116	-96	-95	N/A
6/30/2023	N/A	-106	-87	-86	N/A
3/31/2023	N/A	-98	-93	-87	N/A
12/31/2022	N/A	-92	-94	-85	N/A
9/30/2022	N/A	-86	-94	-84	N/A
6/30/2022	N/A	-81	-92	-83	N/A
3/31/2022	N/A	-78	-79	-74	N/A
12/31/2021	N/A	-70	-73	-69	N/A
9/30/2021	N/A	-70	-69	-65	N/A
6/30/2021	N/A	-65	-61	-56	N/A
3/31/2021	N/A	-56	-53	-48	N/A
12/31/2020	N/A	-49	-40	-36	N/A
9/30/2020	N/A	-36	-31	-28	N/A
6/30/2020	N/A	-26	-25	-23	N/A
3/31/2020	N/A	-19	-17	-15	N/A
12/31/2019	N/A	-13	-11	-10	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: VOR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VOR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VOR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: VOR's revenue (74.1% per year) is forecast to grow faster than the US market (8.6% per year).

High Growth Revenue: VOR's revenue (74.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if VOR's Return on Equity is forecast to be high in 3 years time

Vor Biopharma Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target decreased by 7.2% to US$13.75

Price target decreased by 19% to US$14.82

Price target decreased to US$18.13

Price target decreased to US$21.88

Price target decreased to US$22.25

Price target decreased to US$24.25

Recent updates

Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely

New minor risk - Share price stability

Vor Bio Announces New Clinical Data from Its Ongoing Phase 1/2 VBP101 Study of Patients with Relapsed/Refractory AML Receiving trem-cel Followed by Mylotarg™

Vor Biopharma Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

Vor Biopharma Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

Vor Biopharma Inc.(NasdaqGS:VOR) dropped from Russell Small Cap Comp Value Index

Vor Biopharma Inc. Announces Management Appointments, Effective June 21, 2024

New minor risk - Market cap size

We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

New minor risk - Financial position

Vor Bio Appoints Fouad Namouni to its Board of Directors

Vor Biopharma Inc., Annual General Meeting, May 23, 2024

New major risk - Financial position

Insufficient new directors

Vor Bio Doses First AML Patient with VCAR33 (ALLO)

Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation

Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference

Vor Bio Announces Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio's Novel eHSC and CAR-T Platform

Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?

Price target decreased by 7.2% to US$13.75

New minor risk - Share price stability

Vor Biopharma Inc. Presents Updated Clinical Data from Patients Treated in VBP101

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Price target decreased by 19% to US$14.82

Is Vor Biopharma Inc. (NASDAQ:VOR) Trading At A 49% Discount?

Vor Biopharma Inc. Presents Clinical Data from VBP101

Vor Biopharma Inc. announced that it expects to receive $50 million in funding from RA Capital Management, L.P.

Vor Bio Announces First AML Patient Successfully Transplanted with VOR Bio's Investigational Trem-Cel (Vor33) and Tolerated Mylotarg(Tm)

Price target decreased to US$18.13

We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully

Vor Bio Appoints Eyal C. Attar, M.D. as Chief Medical Officer

Vor Bio appoints Eyal C. Attar as chief medical officer

Price target decreased to US$21.88

Price target decreased to US$22.25

Vor Biopharma Inc.(NasdaqGS:VOR) dropped from Russell 2500 Value Index

Is Vor Biopharma (NASDAQ:VOR) In A Good Position To Invest In Growth?

Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA

Price target decreased to US$24.25

Price target decreased to US$31.71

Vor Biopharma Inc. Announces Retirement of Christopher Slapak as Chief Medical Officer

High number of new directors

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Vor Biopharma Announces VOR33 Granted U.S. FDA Fast Track Designation for Acute Myeloid Leukemia

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Vor Biopharma Expects to Enroll First Patient in VOR33 Acute Myeloid Leukemia Phase 1/2A Clinical Trial in the Next Few Months

Vor Biopharma: Targeted Therapies For Transplants

We're Not Very Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Vor Biopharma EPS misses by $0.03

Vor Biopharma Inc. has completed an IPO in the amount of $176.904306 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies